GSK has paid 465 billion rupiahs to Sarasvati Venture Capital for the 30 percent of the Indonesian consumer healthcare operation it did not previously own, giving it 100 percent of a business that sells non-prescription products like Panadol painkillers and Sensodyne toothpaste.
GlaxoSmithKline is betting more on Indonesia by taking full control of its consumer healthcare unit in the country, underscoring a drive by the drugmaker to build up its presence in fast-growing emerging markets.
The move, announced on Friday, mirrors the British company's strategy in India, where it recently increased its stake in local units.
GSK has paid 465 billion rupiahs to Sarasvati Venture Capital for the 30 percent of the Indonesian consumer healthcare operation it did not previously own, giving it 100 percent of a business that sells non-prescription products like Panadol painkillers and Sensodyne toothpaste.
Also read: GSK Consumer's Crocin Advance set to get cheaper
At the same time, GSK has sold its non-core local Insto eye drops brand to Pharma Healthcare and agreed to divest its factory at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of 133 billion rupiahs.
"This transaction is a further example of GSK focusing its business in strategically important growth markets such as Indonesia. It will also simplify operations in the Indonesian business," David Redfern, GSK's chief strategy officer, said.
GSK's Indonesian consumer healthcare business has seen significant growth over the last five years, with net sales reaching close to 50 million pounds in 2013, up from around 16 million in 2008.
The company is committed to emerging markets as a key growth platform - based on rising demand for healthcare among growing middle class populations - despite recent problems in China, where sales have been hit by bribery allegations.
GlaxoSmithKline stock price
On March 28, 2014, GlaxoSmithKline Pharmaceuticals closed at Rs 2589.10, up Rs 18.40, or 0.72 percent. The 52-week high of the share was Rs 3054.40 and the 52-week low was Rs 2153.30.
The company's trailing 12-month (TTM) EPS was at Rs 59.25 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 43.7. The latest book value of the company is Rs 238.15 per share. At current value, the price-to-book value of the company is 10.87.
Anda sedang membaca artikel tentang
GSK lifts EM bet with full control of Indonesia arm
Dengan url
http://kebugaranhidup.blogspot.com/2014/03/gsk-lifts-em-bet-with-full-control-of.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
GSK lifts EM bet with full control of Indonesia arm
namun jangan lupa untuk meletakkan link
GSK lifts EM bet with full control of Indonesia arm
sebagai sumbernya
0 komentar:
Posting Komentar